Switching from Semaglutide to Tirzepatide: Is It a Good Idea? Hubmed Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide 5mg + Tirzepatide 10mg Injection (15mg)